The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

LUNGevity issues RFA for 2018 Career Development Award in translational research in lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LUNGevity Foundation has issued a Request for Application for translational research in lung cancer for the 2018 Career Development Award.

LUNGevity Career Development Awards support future research leaders who will keep the field of lung cancer research vibrant with new ideas.

The award, for translational early detection or therapeutics projects, including immuno-oncology projects, is open to junior faculty members who are within the first five years of their first faculty appointment.

Successful applicants may receive up to $100,000 per year for a possible period of three years and will participate as ex officio members of LUNGevity’s Scientific Advisory Board for the duration of the award. LUNGevity will grant only one Career Development Award per institution.

The Requests for Applications will be posted as of Jan. 16, 2018, on the LUNGevity website and on the proposalCENTRAL website.

For more information, contact Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

Table of Contents

YOU MAY BE INTERESTED IN

NCI Director's Report

Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
By Jacquelyn Cobb
Capitol Hill

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
By Claire Marie Porter
Guest Editorial

Curing cancer or curbing immigration: A question of national morality and priority

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
By Paul W. Thurman
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account